Experimental Labour-Offshoring Clinical Trials to China
Experimental Labour-Offshoring Clinical Trials to China
复制标题
DOI：
10.1007/s12280-008-9040-y
复制
发表时间：
2008-03-01
影响因子：
0.8
通讯作者：
Cooper, Melinda
中科院分区：
文献类型：
--
作者：
Cooper, Melinda
国家食品药品监督管理局中国报告称，在过去的几年里，多中心、多国临床试验的数量急剧增加。这与临床试验从北美和西欧外包到东欧、中国和印度等非传统地区的日益增长的趋势是一致的。在中国内部，后社会主义医疗改革、内部分工和医疗制度政治化都创造了条件，使签约临床试验工作成为医院和越来越多的未参保工作的当务之急。这篇论文将当前的生物经济创新理论与非正规劳动力和离岸外包的新政治经济学结合在一起，提供了一个重要的见解。它辩称，生产生物经济价值的临床试验阶段在学术描述中经常被忽视，但它是理解当今制药行业投机性过度投资和转换困难的关键。作为重新阐述这一问题的一种方式，论文建议将人体受试者实验重新配置为一种形式的劳动--实验劳动或临床劳动--会更有成效。因此，研究型医院的诊所就成了“体力劳动实验区”中的出口劳务区。
The State Food and Drug Administration of China has reported a dramatic increase in multicentre, multinational clinical trials over the past several years. This is in keeping with a growing trend towards the off-shore outsourcing of clinical trials from North America and Western Europe to 'nontraditional locations' such as Eastern Europe, China, and India. Within China, the post-socialist reform of health care, internal divisions of labour and the politicization of the healthcare system have all created the conditions under which contract clinical trial work is becoming an imperative both for hospitals and the growing number of working uninsured. The paper brings together a critical insight into current theories of bioeconomic innovation with new political economies of informal labour and offshoring. It argues that the clinical trial phase in the production of bioeconomic value is routinely overlooked in scholarly accounts but is key to understanding the speculative overinvestment and translational difficulties of the pharmaceutical industries today. As a way of reformulating the problem, the paper suggests that human subject experimentation would be more fruitfully reconfigured as a form of labour-experimental or clinical labour. The research hospital clinic therefore emerges as an export labour zone in 'experimental body work.'